Anu Cherukuri
Overview
Explore the profile of Anu Cherukuri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Qi Y, Chan M, Mould D, Larimore K, Fisheleva E, Cherukuri A, et al.
Clin Pharmacokinet
. 2024 Apr;
63(5):707-719.
PMID: 38649657
Background And Objective: Vosoritide is a recently approved therapy for achondroplasia, the most common form of disproportionate short stature, that has been shown to be well tolerated and effective in...
2.
Schulz A, Specchio N, de Los Reyes E, Gissen P, Nickel M, Trivisano M, et al.
Lancet Neurol
. 2023 Dec;
23(1):60-70.
PMID: 38101904
Background: Cerliponase alfa is a recombinant human tripeptidyl peptidase 1 (TPP1) enzyme replacement therapy for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), which is caused by mutations...
3.
Pinkstaff J, McCullagh E, Grover A, Melton A, Cherukuri A, Wait J, et al.
Toxicol Rep
. 2023 Mar;
10:357-366.
PMID: 36923444
Mucopolysaccharidosis Type IIIB (MPS IIIB) is an ultrarare, fatal pediatric disease with no approved therapy. It is caused by mutations in the gene encoding for lysosomal enzyme alpha-N-acetylglucosaminidase (NAGLU). Tralesinidase...
4.
Ellinwood N, Valentine B, Hess A, Jens J, Snella E, Jamil M, et al.
J Pharmacol Exp Ther
. 2022 Jun;
382(3):277-286.
PMID: 35717448
Mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome B; OMIM #252920) is a lethal, pediatric, neuropathic, autosomal recessive, and lysosomal storage disease with no approved therapy. Patients are deficient in the...
5.
Chan M, Qi Y, Larimore K, Cherukuri A, Seid L, Jayaram K, et al.
Clin Pharmacokinet
. 2021 Aug;
61(2):263-280.
PMID: 34431071
Background And Objective: Vosoritide, an analog of C-type natriuretic peptide, has been developed for the treatment of children with achondroplasia. The pharmacokinetics of vosoritide and relationships between plasma exposure and...
6.
Kim A, Grover A, Hammon K, de Hart G, Slasor P, Cherukuri A, et al.
Clin Transl Sci
. 2020 Nov;
14(2):635-644.
PMID: 33202105
Cerliponase alfa is recombinant human tripeptidyl peptidase 1 (TPP1) delivered by i.c.v. infusion for CLN2, a pediatric neurodegenerative disease caused by deficiency in lysosomal enzyme TPP1. We report the pharmacokinetics...
7.
Savarirayan R, Irving M, Bacino C, Bostwick B, Charrow J, Cormier-Daire V, et al.
N Engl J Med
. 2019 Jul;
381(1):25-35.
PMID: 31269546
Background: Achondroplasia is a genetic disorder that inhibits endochondral ossification, resulting in disproportionate short stature and clinically significant medical complications. Vosoritide is a biologic analogue of C-type natriuretic peptide, a...
8.
Cherukuri A, Cahan H, de Hart G, Van Tuyl A, Slasor P, Bray L, et al.
Clin Immunol
. 2018 Sep;
197:68-76.
PMID: 30205177
Treatment with intracerebroventricular (ICV)-delivered cerliponase alfa enzyme replacement therapy (ERT) in a Phase 1/2 study of 24 subjects with CLN2 disease resulted in a meaningful preservation of motor and language...
9.
Patton K, Aslam S, Lin J, Yu L, Lambert S, Dawes G, et al.
Clin Vaccine Immunol
. 2014 Feb;
21(5):628-35.
PMID: 24574540
Respiratory syncytial virus (RSV) causes significant disease in elderly adults, and we have previously reported that individuals 65 years of age and older have reduced RSV F protein-specific gamma interferon...
10.
Kurzweil V, Tang R, Galinski M, Wang K, Zuo F, Cherukuri A, et al.
Expert Rev Vaccines
. 2013 Sep;
12(9):1047-60.
PMID: 24053398
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in infants and the elderly. Despite its relatively low degree of antigenic variation, it causes frequent reinfection...